×
Close
Sign Up
Login
Home
People
Photos
Videos
Topics
Bookmarks
Who viewed me
Events
MDLA Events
Event Service
User Tools
FAQ
Questions
User Notes
Feedback
Advertise with Us
Languages
English
中文
French
Português
Español
Arabic
Russian
About Us
Advertising & Media
×
Close
Search Filters
list
All Results
person
Activities
Search Results "#COVId"
Activities
View More Results
Mary Grace N. Tamio (Gra Sya)
on August 19 2023 at 08:37 PM
Edited
public
Prostate cancer drug shows promise against COVID
#prostatecancer
#covid
More info | ⬇️
https://cn1699.com/news/prostate-cancer-drug-shows-promise-against-covid
Prostate cancer drug shows promise against COVID | CN1699
At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link...
0
0
0
0
0
0
0
comment
Comment
thumb_up
Like
share
Share
Mary Grace N. Tamio
on December 07 2022 at 09:24 PM
Edited
public
How antibody therapy affects the breadth of COVID mRNA vaccines
#antibodytherapy
#COVId
#mRNA
More info | ⬇️
https://cn1699.com/news/how-antibody-therapy-affects-breadth-covid-mrna-vaccines
How antibody therapy affects the breadth of COVID mRNA vaccines | CN1699
A new study describes the unique immune response elicited in individuals who received monoclonal antibodies before taking two doses of an mRNA...
0
0
0
0
0
0
0
comment
Comment
thumb_up
Like
share
Share
Mary Grace N. Tamio
on September 06 2022 at 06:20 PM
Edited
public
Having high cholesterol and reduced physical stamina and being overweight are long COVID sequelae in young adults
#highcholesterol
#overweight
#covid
#physicalstamina
More info | ⬇️
https://cn1699.com/news/having-high-cholesterol-and-reduced-physical-stamina-and-being-overweight-are-long-covid
Having high cholesterol and reduced physical stamina and being overweight are long COVID sequelae in young adults | CN1699
A new UZH study conducted with Swiss Armed Forces personnel shows that young people post COVID are likely to have increased cholesterol, a high...
0
0
0
0
0
0
0
comment
Comment
thumb_up
Like
share
Share
Mary Grace N. Tamio
on February 09 2022 at 06:34 PM
Edited
public
Study shows life-saving benefit of baricitinib for ventilated COVID patients
#Baricitinib
#COVID19
#covid
For more information | ⬇️
https://cn1699.com/news/study-shows-life-saving-benefit-baricitinib-ventilated-covid-patients
Study shows life-saving benefit of baricitinib for ventilated COVID patients | CN1699
Critically ill COVID-19 patients on a mechanical ventilator or extracorporeal membrane oxygenation (ECMO) lived more often when randomized to...
0
0
0
0
0
0
0
comment
Comment
thumb_up
Like
share
Share
CN1699 Social Admin
on March 19 2020 at 05:55 PM
Edited
public
新研究发现:新冠肺炎患者发病12天内用克力芝可获益
来自澎湃新闻报道:
3月19日,《新英格兰医学杂志》(NEJM)在线发表中国团队关于使用洛匹那韦/利托那韦治疗重症新冠肺炎患者的临床试验结果,研究结论表明,在重症新冠肺炎成人住院患者中,与常规治疗相比,未观察到洛匹那韦-利托那韦(商品名:克力芝)治疗有益。但是在亚组分析中,发现患者发病12天内使用洛匹那韦/利托那韦,获益趋势更为明显,也为今后的临床试验提供了参考价值。
论文作者是包括中国工程院副院长、中国医学科学院北京协和医学院院校长王辰院士,中日友好医院副院长曹彬,武汉市金银潭医院院长张定宇等人,该研究结果经过严格的同行评议和《新英格兰医学杂志》编辑的审稿和修改,顺利发表。
该研究是在确诊新冠病毒感染的成人住院患者中开展了一项随机、对照、开放标签的试验。研究人员以1:1的比例将患者随机分组,分别接受常规治疗联合14日的每日两次洛匹那韦-利托那韦(分别为400 mg和100 mg)治疗或者单独常规治疗。主要终点是至临床状况改善的时间,其定义为从随机分组至7分等级量表评分改善2分或者出院...
more
新研究发现:新冠肺炎患者发病12天内用克力芝可获益
来自澎湃新闻报道:
3月19日,《新英格兰医学杂志》(NEJM)在线发表中国团队关于使用洛匹那韦/利托那韦治疗重症新冠肺炎患者的临床试验结果,研究结论表明,在重症新冠肺炎成人住院患者中,与常规治疗相比,未观察到洛匹那韦-利托那韦(商品名:克力芝)治疗有益。但是在亚组分析中,发现患者发病12天内使用洛匹那韦/利托那韦,获益趋势更为明显,也为今后的临床试验提供了参考价值。
论文作者是包括中国工程院副院长、中国医学科学院北京协和医学院院校长王辰院士,中日友好医院副院长曹彬,武汉市金银潭医院院长张定宇等人,该研究结果经过严格的同行评议和《新英格兰医学杂志》编辑的审稿和修改,顺利发表。
该研究是在确诊新冠病毒感染的成人住院患者中开展了一项随机、对照、开放标签的试验。研究人员以1:1的比例将患者随机分组,分别接受常规治疗联合14日的每日两次洛匹那韦-利托那韦(分别为400 mg和100 mg)治疗或者单独常规治疗。主要终点是至临床状况改善的时间,其定义为从随机分组至7分等级量表评分改善2分或者出院(以先发生的一项为准)的时间。
该研究包含了共计199例实验室确诊新冠病毒感染的患者被随机分组;99例被分配至洛匹那韦-利托那韦组,100例被分配至常规治疗组。
#Covid
-19
#Coronavirus
#新冠病毒
阅读更多:
https://www.toutiao.com/i6805744081205985806/?tt_from=weixin&utm_campaign=client_share&wxshare_count=2&from=singlemessage×tamp=1584608909&app=news_article&utm_source=weixin&isappinstalled=0&utm_medium=toutiao_ios&req_id=202003191708290100140400892E04178B&group_id=6805744081205985806&pbid=6805852777216198156
新研究发现:新冠肺炎患者发病12天内用克力芝可获益
3月19日,《新英格兰医学杂志》在线发表中国团队关于使用洛匹那韦/利托那韦治疗重症新冠肺炎患者的临床试验结果,研究结论表明,在重症新冠肺炎成人住院患者中,与常规治疗相比,未观察到洛匹那韦-利托那韦治疗有益。
0
0
0
0
0
0
0
comment
Comment
thumb_up
Like
share
Share
Modal title
×
Modal title
×
Share
Login
Global News and Health Forum
Join Now!
Member Login
Remember me
Forgot password?
Or using
Facebook